2.89 0.00 (0.00%)
After hours: 4:59PM EDT
Previous Close | 2.64 |
Open | 2.64 |
Bid | 2.90 x 400 |
Ask | 2.98 x 5000 |
Day's Range | 2.61 - 2.95 |
52 Week Range | 1.64 - 4.51 |
Volume | 2,088,709 |
Avg. Volume | 679,583 |
Market Cap | 296.387M |
Beta | 2.26 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.22 |
Earnings Date | May 8, 2018 - May 14, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.25 |
NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the first patient has been enrolled into its Phase 3 clinical trial (designated as MSK-002) to evaluate the efficacy and safety of Firdapse® (amifampridine phosphate) in patients with MuSK antibody positive Myasthenia Gravis (MuSK-MG).
The Coral Gables-based company is another step closer to bringing a new drug to market.
CORAL GABLES, Fla., March 29, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 6 cents. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
--Firdapse ® NDA to be Resubmitted Before the End of this Quarter. --Significant Progress with MuSK-MG Regulatory and Clinical Program. --$84 M Year-End Cash and Investments.
There are plenty of opportunities to invest in healthcare stocks, as there are thousands of companies, ranging from big and well-established pharmaceuticals that also pay substantial dividends, to small, emerging companies without any products on the market or revenue, but backed by their research into novelty therapies for various illnesses. When looking for healthcare stocks […]
Catalyst Pharmaceuticals Inc’s (NASDAQ:CPRX): Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. With the latest financial year lossRead More...
CORAL GABLES, Fla., March 12, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...
CORAL GABLES, Fla., March 08, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...
Investors focus will be on pipeline and regulatory updates during Catalyst's (CPRX) fourth-quarter earnings call.
CORAL GABLES, Fla., Feb. 28, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carbo ...
Positive meeting with the FDA about the resubmission of an NDA for Firdapse Resubmission of NDA for Firdapse on schedule for end of the first quarter. CORAL GABLES, Fla., Feb. 12, 2018-- Catalyst Pharmaceuticals, ...
CORAL GABLES, Fla., Feb. 07, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...
Can Catalyst, Sucampo, and Peregrine keep the momentum going?
Catalyst Pharmaceuticals, Inc. today announced the pricing of its previously announced underwritten public offering. The Company announced that it is selling 14,285,715 shares of its common stock in the ...
The Coral Gables, Florida-based company said it had a loss of 5 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biotechnology company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. With many analystsRead More...